Related references
Note: Only part of the references are listed.ST-Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII
Krishna Gundabolu et al.
HAEMOPHILIA (2020)
Achieving the unimaginable: Health equity in haemophilia
Mark W. Skinner et al.
HAEMOPHILIA (2020)
In Vitro ELISA and Cell-Based Assays Confirm the Low Immunogenicity of VNAR Therapeutic Constructs in a Mouse Model of Human RA: An Encouraging Milestone to Further Clinical Drug Development
Obinna C. Ubah et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2020)
Case report of a fatal rectal haemorrhage in a person with severe haemophilia A receiving emicizumab and high-dose bypassing agents in the HAVEN 1 study
Liane Khoo et al.
HAEMOPHILIA (2020)
Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: New case with detailed laboratory evaluation
Colleen Harkins Druzgal et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study
Maria Elisa Mancuso et al.
HAEMOPHILIA (2020)
Emicizumab-Induced Seronegative Full-House Lupus Nephritis in a Child
Hassib Chehade et al.
PEDIATRICS (2020)
Emicizumab prophylaxis to facilitate anticoagulant therapy for management of intra-atrial thrombosis in severe haemophilia with an inhibitor
Angela C. Weyand et al.
HAEMOPHILIA (2019)
Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS)
Johnny Mahlangu et al.
HAEMOPHILIA (2019)
Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program
Gallia G. Levy et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)
Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
Jasmine Davda et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Emicizumab and thrombosis: The story so far
Michael Makris et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
Steven W. Pipe et al.
LANCET HAEMATOLOGY (2019)
Central Line-Associated Thrombus Formation in an Inhibitor Negative Severe Hemophilia A Patient on Emicizumab
Nicholas B. George et al.
BLOOD (2019)
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
Guy Young et al.
BLOOD (2019)
Emicizumab: Review of the literature and critical appraisal
E. Carlos Rodriguez-Merchan et al.
HAEMOPHILIA (2019)
Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations
Koji Yada et al.
JOURNAL OF BLOOD MEDICINE (2019)
Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee
P. W. Collins et al.
HAEMOPHILIA (2018)
Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab
K. Nogami et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents
R. Hartmann et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
J. Mahlangu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A
Tristan Knight et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2018)
Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies
Ido Paz-Priel et al.
BLOOD (2018)
The role of patient and healthcare professionals in the era of new hemophilia treatments in developed and developing countries
Fadi Nossair et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2018)
Thrombotic microangiopathies: a general approach to diagnosis and management
Donald M. Arnold et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2017)
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Johannes Oldenburg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Treatment adherence in hemophilia
Courtney D. Thornburg et al.
PATIENT PREFERENCE AND ADHERENCE (2017)
Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
Peter J. Lenting et al.
BLOOD (2017)
Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors
Midori Shima et al.
BLOOD ADVANCES (2017)
From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals
G. R. Gunn et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A
Midori Shima et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
Emilie M. J. van Brummelen et al.
ONCOLOGIST (2016)
Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels
Meghna Jani et al.
RHEUMATOLOGY (2016)
Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab
Barry D. Hock et al.
THERAPEUTIC DRUG MONITORING (2016)
Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches
Shannon L. Meeks et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes
Murli Krishna et al.
FRONTIERS IN IMMUNOLOGY (2016)
Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia A
Pratima Chowdary et al.
JOURNAL OF BLOOD MEDICINE (2016)
Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens
Johannes Oldenburg
BLOOD (2015)
Costs and utilization of treatment in patients with hemophilia
Patricia Rocha et al.
BMC HEALTH SERVICES RESEARCH (2015)
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
Johnny Mahlangu et al.
BLOOD (2014)
Safety of recombinant activated factor VII ( rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg-1) rFVIIa doses across clinical trials and registries
A. D. Shapiro et al.
HAEMOPHILIA (2014)
Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions
Alessandra Vultaggio et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2014)
Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B
Jonathan M. Ducore et al.
EXPERT REVIEW OF HEMATOLOGY (2014)
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A
Corien L. Eckhardt et al.
BLOOD (2013)
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B
Jerry S. Powell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Healthcare resource utilization among haemophilia A patients in the United States
L. A. Valentino et al.
HAEMOPHILIA (2012)
Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes
Amy D. Shapiro et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2011)
Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR
Takuo Suzuki et al.
JOURNAL OF IMMUNOLOGY (2010)
Pathogenesis of thrombotic microangiopathies
X. Long Zheng et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2008)
Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors
T. Abshire et al.
HAEMOPHILIA (2008)
Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients
V. S. Blanchette et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors
T Abshire et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
Inhibitors: resolving diagnostic and therapeutic dilemmas
D Dimichele
HAEMOPHILIA (2002)
Share Paper
